Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A Johnson & Johnson subsidiary downplayed and hid risks associated with the antipsychotic drug Risperdal, a jury determined Tuesday in Arkansas' billion-dollar lawsuit against Janssen Pharmaceuticals Inc.
Arkansas Attorney General Dustin McDaniel's office is seeking fines of at least $1.2 billion for the 250,000 Risperdal prescriptions the state's Medicaid program paid for over 3 1/2 years. The penalty will be decided in a separate hearing before Circuit Judge Tim Fox, who presided over the trial.
The 12-person jury returned its verdict about three hours after it started deliberating. Jurors had heard 10 days of testimony. They weren't told about the financial stakes, beyond that Janssen could have seen a $200 million swing in its revenues if it issued alarming warnings that the drug could cause weight gain, diabetes and other health effects.
http://www.businessweek.com/ap/2012-04/D9U2AJH83.htm
Arkansas Attorney General Dustin McDaniel's office is seeking fines of at least $1.2 billion for the 250,000 Risperdal prescriptions the state's Medicaid program paid for over 3 1/2 years. The penalty will be decided in a separate hearing before Circuit Judge Tim Fox, who presided over the trial.
The 12-person jury returned its verdict about three hours after it started deliberating. Jurors had heard 10 days of testimony. They weren't told about the financial stakes, beyond that Janssen could have seen a $200 million swing in its revenues if it issued alarming warnings that the drug could cause weight gain, diabetes and other health effects.
http://www.businessweek.com/ap/2012-04/D9U2AJH83.htm